A Phase IV Study to Assess the Safety of EupentaTM Inj

PHASE4UnknownINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

September 23, 2019

Primary Completion Date

October 12, 2020

Study Completion Date

December 31, 2020

Conditions
Hepatitis BDiphtheriaHaemophilus Influenzae Type B InfectionTetanusPertussis
Interventions
BIOLOGICAL

Eupenta Inj.

fully liquid pentavalent vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA \[recombinant-deoxyribonucleic acid\])-Haemophilus influenzae type b conjugate vaccine single dose 0.5 mL/vial The vaccine is given at 6, 10 and 14 weeks of age in infants.

Sponsors

Lead Sponsor

All Listed Sponsors
lead

LG Chem

INDUSTRY

NCT04056728 - A Phase IV Study to Assess the Safety of EupentaTM Inj | Biotech Hunter | Biotech Hunter